321EGP
- Active ingredient
- empagliflozin+linagliptin
- Strength
- 10/5mg
- Form
- tablet
- Manufacturer
- global napi pharmaceuticals
- Route
- oral.solid
Uses
Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Do not use if
Contraindicated in severe hypersensitivity to either component and generally not recommended in severe renal impairment.
Side effects
Urinary tract infections, genital fungal infections, increased urination, and nasopharyngitis may occur.
Warnings
Monitor for ketoacidosis, dehydration, pancreatitis, and serious urinary infections.
How it works
Combines an SGLT2 inhibitor that increases urinary glucose excretion with a DPP-4 inhibitor that enhances incretin activity.
Storage
Store at 20–25°C and protect from excessive humidity.